|Sales (in € mil.)||5,047.8||4,609.4||9.5|
|Profit After Functional Expenses (in € mil.)||477.2||453.1||5.3|
|EBITDA (in € mil.)||757.5||691.3||9.6|
|Research and Development Expenses (in € mil.)||191.4||179.9||6.6|
|Equity Ratio (%)||41.2||40.9|
|Number of Employees||46,559*||43,676||6.6|
Sales: 5,047.8 million (+ 9.5 percent)
Profit After Functional Expenses: 477.2 million (+ 5.3 percent)
Operating Profit: 469.2 million (+ 7.9 percent)
Consolidated Annual Net Profit: 288.6 million (+ 12.0 percent)
Net Opertating Margin: 5.7 percent
Investments in Property, Plant and Equipment and Intangible Assets: 588.5 million (+ 2.7 percent)
Depreciation of Property, Plant and Equipment and Intangible Assets: 279.1 million (+ 10.4 percent)
Equity Ratio: 41.2 percent
Personnel Expenditure: 1,834.4 million (+ 11.2 percent)
Number of Employees (as of Dec 31, 2012): 46,559 (+ 6.6 percent)
The Hospital Care Division offers integrated therapy concepts of products and services for anaesthesia, intensive and acute care, infusion therapy and urology; annual sales of € 2,412.7 million (+ 11.7 %).
Sales of the Aesculap Division, system supplier in the surgical area, rose to €1,442.5 million (+ 6.4 %).
Out Patient Market Division (OPM) offers concepts of comprehensive patient care for the segment of physicians in private practice as well as out-patient and stationary care. Annual sales of €606.2 million (+ 6.6 %).
B. Braun Avitum, active in the field of extracorporeal blood treatment and dialysis, provider of dialysis centers throughout Europe; sales of €559.2 million means an increase of 11.7 percent in comparison to the previous year.